Aura Biosciences Past Earnings Performance

Past criteria checks 0/6

Aura Biosciences's earnings have been declining at an average annual rate of -24.6%, while the Biotechs industry saw earnings growing at 19.3% annually.

Key information

-24.6%

Earnings growth rate

86.1%

EPS growth rate

Biotechs Industry Growth	17.0%
Revenue growth rate	n/a
Return on equity	-47.6%
Net Margin	n/a
Last Earnings Update	30 Sep 2024

Recent past performance updates

No updates

Recent updates

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Mar 28

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Oct 01

Aura gains as JMP starts with Bullish view citing treatment platform

Jul 19

Aura Biosciences' AU-011 gets FDA fast-track status for bladder cancer

Jun 30

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Apr 10

Revenue & Expenses Breakdown

How Aura Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGM:AURA Revenue, expenses and earnings (USD Millions)
Date	Earnings	G+A Expenses	R&D Expenses
30 Sep 24	-83	22	71
30 Jun 24	-81	21	70
31 Mar 24	-79	20	68
31 Dec 23	-76	20	65
30 Sep 23	-71	20	58
30 Jun 23	-68	19	54
31 Mar 23	-63	19	48
31 Dec 22	-59	18	42
30 Sep 22	-55	17	37
30 Jun 22	-52	15	32
31 Mar 22	-51	13	29
31 Dec 21	-46	10	25
30 Sep 21	-40	8	21
30 Jun 21	-33	6	17
31 Mar 21	-29	5	16
31 Dec 20	-30	4	18

Quality Earnings: AURA is currently unprofitable.

Growing Profit Margin: AURA is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: AURA is unprofitable, and losses have increased over the past 5 years at a rate of 24.6% per year.

Accelerating Growth: Unable to compare AURA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AURA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).

Return on Equity

High ROE: AURA has a negative Return on Equity (-47.64%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/27 09:36
End of Day Share Price	2024/12/27 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aura Biosciences, Inc. is covered by 6 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Liisa Bayko	Evercore ISI
Edward White	H.C. Wainwright & Co.
Jonathan Wolleben	JMP Securities

Aura Biosciences Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Recent updates

Aura Biosciences, Inc. Announces Positive Early Data from an Ongoing Phase 1 Clinical Trial of Bel-sar (AU-011) in Patients with NMIBC

Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company

Aura Biosciences, Inc. Reports Positive Phase 2 End of Study Results Evaluating Bel-Sar as A First- Line Treatment for Early-Stage Choroidal Melanoma

We're Hopeful That Aura Biosciences (NASDAQ:AURA) Will Use Its Cash Wisely

Aura Biosciences, Inc., Annual General Meeting, Jun 20, 2024

Aura Biosciences, Inc., Annual General Meeting, Jun 20, 2024

New minor risk - Insider selling

Founder recently sold US$121k worth of stock

Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-Sar) for First-Line Treatment of Early-Stage Choroidal Melanoma

Independent Chairman of the Board recently bought US$1.4m worth of stock

Founder notifies of intention to sell stock

Aura Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $99 million.

Aura Biosciences, Inc. has filed a Follow-on Equity Offering.

New minor risk - Share price stability

Founder recently sold US$65k worth of stock

Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023

Independent Chairman of the Board recently bought US$168k worth of stock

Aura Biosciences, Inc. Announces Executive Changes

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Aura Biosciences, Inc. Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration At the Macula Society 46Th Annual Meeting

Aura Announces Inc. Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma

Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Au-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented At Aao 2022

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Aura Biosciences Inc. to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress

Aura gains as JMP starts with Bullish view citing treatment platform

Aura Biosciences Receives Fda Fast Track Designation for Belzupacap Sarotalocan (Au-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Aura Biosciences' AU-011 gets FDA fast-track status for bladder cancer

Aura Biosciences, Inc.(NasdaqGM:AURA) dropped from Russell 2500 Value Index

Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AUu-011) Versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma

Aura Biosciences Present Updates Belzupacap Sarotalocan (Au-011) Data on Multiple Studies At the International Society of Ocular Oncology 2022 Bi-Annual Meeting

Independent Chairman of the Board recently bought US$716k worth of stock

Aura Biosciences, Inc. Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting

Aura Biosciences, Inc. Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Aura Biosciences, Inc. to Present Preclinical Data Demonstrating Applicability of AU-011 in Bladder Cancer at the 2022 ASCO Genitourinary Cancer Symposium

Revenue & Expenses Breakdown

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources